These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28731881)

  • 61. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
    Abou-Alfa GK; Venook AP
    Lancet Oncol; 2013 Jun; 14(7):e283-8. PubMed ID: 23725711
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature.
    Ensslin CJ; Kao PH; Wu MY; Chang YY; Kuo TT; Hsieh CH; Hsieh SY; Yang CH; Miller LS
    Cutis; 2019 Sep; 104(3):E11-E15. PubMed ID: 31675404
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
    Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
    Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
    Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
    Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Naganuma A; Hoshino T; Suzuki Y; Uehara D; Kudo T; Ishihara H; Sato K; Kakizaki S; Yamada M; Takagi H
    Acta Med Okayama; 2017 Aug; 71(4):291-299. PubMed ID: 28824184
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
    Abdel-Rahman O; Lamarca A
    Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):75-83. PubMed ID: 27882800
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
    Di Costanzo GG; Tortora R; Iodice L; Lanza AG; Lampasi F; Tartaglione MT; Picciotto FP; Mattera S; De Luca M
    Dig Liver Dis; 2012 Sep; 44(9):788-92. PubMed ID: 22579445
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
    Kim JW; Lee JO; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Am J Clin Oncol; 2011 Apr; 34(2):125-9. PubMed ID: 20308869
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
    Zheng SZ; Liu DJ; Sun P; Yu GS; Xu YT; Gong W; Liu J
    World J Gastroenterol; 2014 Nov; 20(43):16275-81. PubMed ID: 25473183
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
    Ganten MK; Schuessler M; Bruckner T; Ganten TM; Koschny R
    Oncology; 2015; 89(2):88-94. PubMed ID: 25871578
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.
    Kim JE; Ryoo BY; Ryu MH; Chang HM; Suh DJ; Lee HC; Lim YS; Kim KM; Kang YK
    Oncology; 2012; 82(2):119-25. PubMed ID: 22354124
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients.
    Lesmana LA; Gani RA; Hasan I; Waspodo A; Boedi P; Luwia MS; Ganggaiswari A
    Acta Med Indones; 2012 Jul; 44(3):228-32. PubMed ID: 22983078
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Nodulocystic eruption induced by sorafenib].
    Chambelland A; Koeppel MC; Desmedt E; Fongue J; Buono JP; Berbis P; Delaporte E
    Ann Dermatol Venereol; 2019 Oct; 146(10):646-654. PubMed ID: 31362839
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rhabdomyolysis in a patient under treatment with sorafenib.
    Díaz Alcázar MDM; Cervilla Sáez de Tejada E; Ruiz Escolano E
    Rev Esp Enferm Dig; 2020 Mar; 112(3):243-244. PubMed ID: 31960700
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study.
    Reig M; Sanduzzi-Zamparelli M
    Lancet Oncol; 2022 Jan; 23(1):4-6. PubMed ID: 34914890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.